A workshop, ''Chemopreventive properties of nonsteroidal anti -inflammatory drugs ( NSAIDs ): Role of COXdependent and -independent mechanisms,'' sponsored by the Chemical and Physical Carcinogenesis Branch,
Background
Multiple lines of evidence suggest that nonsteroidal antiinflammatory drugs ( NSAIDs ) reduce the risk of colorectal cancer and possibly other types of cancer. Results from genetic and pharmacological studies suggest that the antitumor effects of NSAIDs are mediated, at least in part, through inhibition of cyclooxygenase ( COX ), the rate -limiting enzyme in prostaglandin ( PG ) biosynthesis. However, other results suggest that the chemopreventive effects of NSAIDs are also mediated through COX -independent mechanisms. Thus, the workshop was designed to bring together investigators working in this area to: 1 ) evaluate recent experimental evidence supporting COX -dependent and -independent mechanisms underlying the chemopreventive activity of NSAIDs; 2 ) identify important issues that need to be resolved to clarify and enhance our understanding of these mechanisms; 3 ) define the directions for future research to advance the field; and 4 ) encourage collaboration among investigators using the National Cancer Institute ( NCI ) Activities to Promote Research Collaborations initiative.
COX -Dependent Mechanisms
Raymond DuBois ( Vanderbilt University, Nashville, TN ) discussed evidence suggesting that the anticancer effects of NSAIDs are mediated through COX -dependent mechanisms [ 1 ] . He emphasized that in population -based studies, the intake of low doses of aspirin reduced the incidence of colorectal cancer. This finding suggests that the protective effect of aspirin is mediated through inhibition of COX. Dr. DuBois suggested that COX -2 was an important pharmacological target of NSAIDs. He noted that increased amounts of COX -2 are detected in various solid tumors including colorectal cancer [ 2 ] . Overexpression of COX -2 appears to be a consequence of increased transcription [ 3 ] and possibly enhanced stability of COX -2 message [ 4 ] . The discovery of a correlation between amounts of COX -2 in human lung and colon cancers and patient prognosis was cited as further evidence of the potential importance of COX -2 as a target for therapy [ 5, 6 ] . Dr. DuBois noted that overexpression of COX -2 in intestinal epithelial cells inhibited apoptosis and stimulated angiogenesis -properties that enhance tumorigenesis [ 7, 8 ] . Finally, he indicated that his group had shown that treatment with a selective COX -2 inhibitor suppressed the growth of experimental colorectal carcinoma without detrimental effects to the normal intestine [ 9 ] . Jaime Masferrer ( Pharmacia Co., St. Louis, MO ) presented evidence that celecoxib, a selective COX -2 inhibitor, reduced tumor growth and metastasis in xenograft tumor models [ 10 ] . He suggested that the antineoplastic activity of celecoxib can be explained, in part, by inhibition of angiogenesis [ 8, 10 ] . This idea was supported by several findings. The observation that PGs stimulate the production of vascular endothelial growth factor ( VEGF ) was reviewed [ 11 ] . Additionally, Dr. Masferrer indicated that COX -2 was expressed in the neovasculature of transplantable tumors in experimental animals. His laboratory also showed that celecoxib blocked basic fibroblast growth factor -induced neovascularization and PG biosynthesis in the rat cornea [ 10 ] . Inhibition of neovascularization was associated with decreased cell proliferation and increased apoptosis.
Daniel Simmons ( Brigham Young University, Provo, UT ) discussed results demonstrating that nucleobindin ( Nuc ) can bind COX when Nuc and COX -1 or COX -2 were ectopically coexpressed in COS -1 cells [ 12 ] . Nuc has been postulated to function in apoptosis as well as to control calcium homeostasis in the cis -Golgi. Although the functional significance of Nuc -COX interaction is unknown, this could represent a PG -independent signaling mechanism. In theory, NSAIDs could bind to COX and thereby alter protein -protein interactions.
Daniel Hwang ( Pennington Biomedical Research Center, Baton Rouge, LA ) presented evidence that COX -2 gene expression could be a target of NSAIDs via PG -independent mechanisms. He noted that certain NSAIDs, such as flufenamic acid and sulindac sulfide, inhibited cytokinemediated induction of COX -2 in HT -29 human colon cancer cells [ 13 ] . This suppressive effect was mediated, at least in part, through inhibition of NF -B. NSAIDs that inhibited NF -B signaling also suppressed mitogen -induced expression of COX -2 and other proinflammatory molecules including iNOS and IL -1 in macrophage -like RAW 264.7 cells. Macrophages, an important stromal cell in tumor tissues, can release cytokines that, in turn, stimulate the expression of COX -2 in tumor cells and other stromal cells. Possibly, NSAIDs inhibit both the production of cytokines by macrophages, and the induction of COX -2 by tumor cells in response to cytokines. Dr. Hwang postulated that NSAIDs may act not only by inhibiting COX enzyme activity but also by suppressing the expression of COX -2 and other proinflammatory gene products [ 13 ] .
COX -Independent Mechanisms
Although there is convincing evidence that overexpression of COX -2 is linked to tumorigenesis, it is not clear whether the antitumor effects of NSAIDs result entirely from inhibition of COX activity. For example, high concentrations of NSAIDs inhibit the growth of cell lines that do not express either COX -1 or COX -2 [ 14 ] . Several investigators described COX -independent effects of NSAIDs that may contribute to the anticancer activity of these agents.
I. Bernard Weinstein ( Columbia University, New York, NY ) reported that sulindac sulfone, a metabolite of the NSAID sulindac that does not inhibit COX activity, induces growth inhibition and apoptosis in cancer cell lines and also inhibits tumorigenesis in experimental animals [ 15 -18 ] . Moreover, sulindac sulfone was evaluated in patients with a history of prostate cancer and rising serum PSA levels. Sulindac sulfone -treated patients displayed a significant decrease in PSA levels compared with the placebo control group. Mechanistic studies done by his group in collaboration with investigators at Cell Pathways, Inc. showed that sulindac sulfone and related compounds induced apoptosis through inhibition of cGMP -specific phosphodiesterases PDE2 and PDE5. This led, in turn, to increased levels of cGMP and activation of protein kinase G [ 17 ] . Activation of protein kinase G then induces apoptosis, at least in part, through activation of JNK1 [ 18 ] .
Richard Gaynor ( University of Texas Southwestern Medical School, Dallas, TX ) reviewed evidence that selected NSAIDs block the activation of NF -B. The NF -B transcription factors regulate the expression of a spectrum of genes implicated in both inflammation and carcinogenesis. He reported that aspirin and salicylate inhibited the activity of IKK , thereby preventing IB phosphorylation and NF -B activation [ 19 ] . In addition, sulindac sulfide inhibited both IKK and IKK kinase activity and induced apoptosis in a colon cancer cell line ( HCT -15 ) that lacks COX -2. By contrast, neither indomethacin nor ibuprofen inhibited IKK kinase activity. These results suggest that in addition to inhibiting COXs, selected NSAIDs may target the NF -B pathway. Evidence was also presented of potential crosstalk between the NF -B and -catenin pathways. Hence, NSAIDs may directly or indirectly alter a variety of signal transduction pathways that are implicated in cancer.
Kenneth Kinzler and colleagues ( Johns Hopkins, Baltimore, MD ) have identified other molecular targets of NSAIDs. He reported that the apoptotic response to the chemopreventive agent, sulindac, and other NSAIDs was completely abolished in human colorectal cancer cells that lack functional BAX [ 20 ] . NSAIDs inhibited the expression of the antiapoptotic protein, Bcl -X L , resulting in a substantial increase in the ratio of BAX:Bcl -X L and subsequent apoptosis through a mitochondrial pathway [ 20 ] . In addition, he reported that PPAR is one of the targets of both APC and NSAIDs in human colorectal cancer cells [ 21 ] . Normally, APC downregulates the expression of PPAR. Hence, increased amounts of PPAR are detected frequently in colorectal cancers because APC mutations are common in this disease. Treatment with NSAIDs, such as sulindac sulfide and indomethacin, compensated, in part, for an APC mutation by disrupting the DNA binding activity of PPAR. Furthermore, overexpression of PPAR partially rescued colorectal cancer cells from sulindac sulfide -induced apoptosis. To more fully evaluate the role of PPAR in mediating sulindac sulfide -induced apoptosis, additional experiments were performed. Genetic disruption of PPAR in a human colorectal cancer cell line did not alter the sensitivity of the cells to NSAIDs [ 22 ] . When inoculated as xenografts in nude mice, PPAR À / À cells exhibited a decreased ability to form tumors compared with PPAR + / À and wild -type controls [ 22 ] . These results suggest that PPAR is a promising target for drug development. Once the relationship between in vitro apoptosis caused by NSAIDs and in vivo chemoprevention is better understood, the significance of NSAID -mediated inhibition of PPAR should become clearer.
NCI Research Plans for NSAIDs
Ernest Hawk of the NCI presented an overview of the current status and future plans for NSAIDs as chemopreventive and therapeutic agents with respect to NCI's research portfolio. Despite an impressive body of mechanistic, observational, and experimental evidence demonstrating the anticancer properties of NSAIDs, these agents are not routinely prescribed for cancer prevention because of several fundamental deficits in our knowledge. It is not known which specific agent( s ) is most effective, or importantly, what dose or length of treatment should be recommended for cancer prevention. In addition, traditional NSAIDs are associated with several well -known risks, including gastric ulceration, renal and platelet dysfunction, making them less appealing for preventive as opposed to therapeutic applications. Attempts to improve the therapeutic index ( i.e., benefit:risk ratio ) of COX inhibitors include: 1 ) testing agents with greater mechanistic specificity such as COX -2 selective inhibitors ( or other NSAID derivatives ); 2 ) performing careful downward dose titrations of traditional COX inhibitors; 3 ) applying COX inhibitors regionally rather than systemically; and 4 ) testing COX inhibitors in combination with other chemopreventive agents.
Looking to the future, the NCI has a substantial research portfolio related to the identification, testing, and development of NSAIDs and NSAID derivatives as preventive agents. This portfolio includes: 1 ) basic science studies to further elucidate the key mechanisms( s ) associated with NSAID efficacy; 2 ) preclinical studies of various NSAIDs to establish their efficacy against preinvasive and invasive neoplasia; and 3 ) clinical trials evaluating NSAIDs, COX -2 selective inhibitors, NSAID derivatives, and corticosteroids ( which inhibit the expression of COX -2 ) in several different cohorts at risk for cancer of the colorectum, duodenum, esophagus, oral mucosa, lung, skin, or prostate. While the NCI has focused on cancer prevention, it is important to recognize that COX inhibitors offer several other potential health benefits including analgesia, cardiovascular prevention, and possibly, preventive effects in cognitive disorders ( e.g., Alzheimer's disease ). Indeed, the appropriate administration of NSAIDs, COX -2 selective inhibitors, or both in persons at risk for these common diseases is a challenging research endeavor, which has the potential for significant public health rewards.
Group Discussion Session: Key Issues and Questions 1. Abundant evidence suggests that COX is one of the critical targets that mediate the chemopreventive and antitumor effects of NSAIDs. A key question then is whether overexpression of COX in vivo is sufficient to induce tumorigenesis. COX -2 has been reported to be important in mediating angiogenesis, immune suppression, and resistance to apoptosis. These effects can be reversed by treatment with an NSAID. What is the relative importance of these different effects? Could they differ in the colon versus other tissues, e.g., lung?
Timothy Hla ( University of Connecticut School of Medicine, Farmington, CT ) reported that overexpression of COX -2 in mammary tissue was sufficient to cause breast cancer in multiparous mice [ 23 ] . Susan Fischer ( MD Anderson Cancer Center, Science Park, TX ) reported that transgenic expression of COX -2 under the control of the keratin 14 promoter led to prostatic lesions consistent with prostatic intraepithelial neoplasia. These findings support the idea that COX -2 may represent a pharmacological target in several premalignant and malignant conditions in addition to colorectal neoplasia.
Steven Dubinett ( UCLA School of Medicine, Los Angeles, CA ) discussed evidence that overexpression of COX -2 in tumor cells can inhibit cell -mediated immunity [ 24 -27 ] . He reported that elevated production of PGE 2 by tumor cells enhanced the production of IL -10 by lymphocytes and macrophages while simultaneously inhibiting the production of IL -12 by macrophages. IL -10 inhibits important aspects of cellular immunity, whereas IL -12 induces type 1 cytokine production and effective antitumor cell -mediated responses. Moreover, abrogation of COX -2 expression was found to promote antitumor reactivity by restoring the balance of IL -10 and IL -12 in vivo. Taken together, these findings indicate that COX -2 -derived PGs can have important immunomodulatory effects that are protumorigenic. The relative importance of these immunosuppressive effects, compared with other known effects of PGs, e.g., stimulation of angiogenesis or inhibition of apoptosis, remains uncertain. Whether different mechanisms are operative in different malignancies or stages of carcinogenesis continues to be investigated.
2. Is COX -1, in addition to COX -2, linked to tumorigenesis? Although the design of the clinical studies differ, celecoxib may have been less effective than sulindac in causing regression of adenomas in subjects with FAP [ 28, 29 ] . How important, therefore, is COX -1 inhibition for understanding the activity of NSAIDs?
Overexpression of COX -2 has been observed in numerous human malignancies. COX -1 is normally expressed in most cells and its kinetic parameters are virtually identical to those of COX -2. Hence, knocking out the COX -2 gene or selectively inhibiting COX -2 is not anticipated to completely block the synthesis of prostanoids in tumor tissues. It is logical to wonder, therefore, whether NSAIDs that are dual COX -1 / COX -2 inhibitors will be more effective antitumor agents than selective inhibitors of COX -2.
Robert Langenbach ( NIEHS, Research Triangle Park, NC ) reported that homologous disruption of either COX -1 or COX -2 reduced polyp formation in Min / + mice by about 80% [ 30 ] . PGE 2 levels were increased in polyps compared with normal tissue, and both COX -1 and COX -2 contributed to the PGE 2 that was produced. These results suggest that COX -1, in addition to COX -2, plays a significant role in intestinal tumorigenesis and that COX -1 may also be a target of NSAIDs. Jaime Masferrer mentioned that his group had found that selective inhibitors of COX -2 were more effective than traditional NSAIDs in suppressing tumor growth in xenograft models. Robert Langenbach indicated that selective inhibitors of COX -2 were not always more effective than dual COX -1 / COX -2 inhibitors. He also pointed out that there was a fundamental difference between studies of xenografted tumors and his knockout experiments. In the xenograft model, tumor cells are transplanted and hence COX inhibitors must suppress tumorigenesis by reducing tumor growth. By contrast, in his COX knockout experiments, the formation of endogenous tumors was assessed. In this instance, COX deficiency could reduce tumor formation because of inhibitory effects on the initiation or promotion stages of tumorigenesis.
3. Although the antitumor effects of NSAIDs are well documented, there is debate as to the relative importance of COX -dependent versus COX -independent mechanisms of action. How convincing is the evidence that the antitumor effects of NSAIDs are mediated, in part, by PPARs or inhibition of cGMP phosphodiesterases? Are changes in intracellular levels of arachidonate important for mediating the antitumor effects of NSAIDs? What are the limitations of the data suggesting that NSAIDs may mediate their anticancer effects, in part, by COX -independent mechanisms? Are there experiments that can be done to help resolve this issue?
If the antitumor effects of NSAIDs are mediated, in part, through COX -independent pathways, the key question is ''What are the other potential molecular targets of NSAIDs?'' PPARs represent one possible target. NSAIDs can activate PPAR and [ 31 ] -nuclear receptors that regulate the transcription of a diverse array of genes including those involved in inflammation and growth. Several in vitro studies have shown that ligands of PPAR inhibit the growth of various cancer cell lines [ 32, 33 ] . Consistent with these findings, the growth of cancer cell lines transplanted into nude mice is suppressed by treatment with PPAR ligands [ 34 ] . These findings suggested that activating PPAR could protect against tumor formation. However, conflicting results were obtained in pharmacological studies in Min mice [ 35, 36 ] . In this model, treatment with a PPAR ligand led to a modest increase in the number of colonic polyps -an effect that was not observed in prior studies of either NSAIDs or selective COX -2 inhibitors [ 37, 38 ] .
Geoffrey Girnun, a member of Bruce Spiegelman's laboratory ( Dana -Faber Cancer Institute, Boston, MA ), presented new evidence that PPAR could represent a pharmacological target for inhibiting colorectal cancer. He reported the effects of treating PPAR wild -type and PPAR ( + / À ) mice with azoxymethane, a well -known colon carcinogen. PPAR ( + / À ) mice developed colorectal cancer faster than PPAR wild -type mice. There were also a greater number of tumors / mouse in the PPAR heterozygous mice. These data suggested that PPAR could represent a tumor -suppressor gene. Possibly, high doses of NSAID cause an endogenous PPAR ligand to accumulate, which, in turn, activates PPAR. Questions were raised about the possible identity of an endogeneous PPAR ligand, but this remains uncertain.
These results and those presented by Dr. Kinzler suggest that PPAR and could be relevant targets of NSAIDs. The observation that NSAIDs activate PPAR while inhibiting PPAR raised some critical questions relating to how NSAIDs modulate the activity of different PPARs and the target genes that are differentially expressed. It was agreed that further research is needed to 1 ) establish the importance of PPARs as therapeutic targets for preventing or treating cancer and 2 ) determine whether the antitumor effects of NSAIDs are mediated, in part, by effects on PPARs.
Joseph Thompson ( Cell Pathways, Inc., Horsham, PA ) stressed that sulindac sulfone, a metabolite of sulindac that does not inhibit COX, induced apoptosis by inhibiting cGMP phosphodiesterases. These findings raise additional questions that should be answered. For example, do other inhibitors of cGMP phosphodiesterases induce apoptosis? Which NSAIDs, if any, inhibit cGMP phosphodiesterases and induce apoptosis?
Frank Fitzpatrick ( University of Utah, Salt Lake City, UT ) stated that recent work in the laboratory of Stephen Prescott suggests that NSAIDs induce apoptosis by causing free arachidonic acid to accumulate, rather than simply inhibit the production of PGs [ 39 ] . This idea is based on several lines of evidence: 1 ) exogenous arachidonic acid caused apoptosis in colon cancer and other cell lines; and 2 ) triacsin C, an inhibitor of fatty acid -CoA lipase ( FACL4 ), an arachidonic acid -utilizing enzyme, induced apoptosis. Additionally, overexpression of FACL4 or COX -2 as ''sinks'' for unesterified arachidonic acid blocked apoptosis; and 3 ) treatment with indomethacin and sulindac enhanced the apoptosisinducing effect of triacsin C. It was concluded that modulating the cellular level of unesterified arachidonic acid is a general mechanism by which apoptosis is regulated, and that COX -2 and FACL4 promote carcinogenesis by lowering the level of free arachidonic acid. Hence, NSAIDs could inhibit tumorigenesis, in part, by increasing the levels of unesterified arachidonic acid in cells. Whether arachidonic acid or its metabolites stimulate apoptosis is an important question that requires additional investigation. Additional research will be required to understand how much of the anticancer activity of NSAIDs can be attributed to reduced PG production versus increased levels of arachidonate in cells.
Jilly Evans ( Merck Research Laboratories, West Point, PA ) reviewed both genetic [ 40 ] and pharmacological [ 41 ] data suggesting that COX -2 is the primary target of NSAIDs. She cited evidence that knocking out the COX -2 gene protected against intestinal tumorigenesis in a murine model of familial adenomatous polyposis [ 40 ] . Moreover, rofecoxib, a selective COX -2 inhibitor, at blood concentrations equivalent to those achieved in humans at clinical steady -state dosing of 25 mg, once per day, decreased polyp number by 55% in Apc Á716 mice [ 41 ] . Rofecoxib was at least as effective as sulindac in inhibiting polyp number; it also reduced DNA replication and amounts of VEGF in polyps. Lawrence Marnett ( Vanderbilt University, Nashville, TN ) also discussed findings from his laboratory suggesting the importance of COX -2 as a therapeutic target. He commented on the development of o -( acetoxyphenyl )hept -2 -ynyl sulfide ( APHS ), an aspirin -like molecule that covalently inactivates COX -2 [ 42 ] . Relative to aspirin, APHS was 60 times as reactive against COX -2 and 100 times as selective for its inhibition. The effects of APHS on the growth of colon cancer cell lines were assessed in soft agar. Consistent with the idea that COX -2 is important for the growth of tumor cells, APHS inhibited the growth of a colon cancer cell line ( HCA -7 ) expressing COX -2. By contrast, APHS did not inhibit the growth of a colon cancer cell line ( HCT -15 ) that does not express COX -2.
Several investigators raised concerns that the evidence supporting the COX -independent effects of NSAIDs was based primarily on results in which very high concentrations of NSAID were used in vitro. Raymond DuBois and Andrew Dannenberg questioned the clinical relevance of experiments demonstrating that high concentrations ( >100 M ) of NSAIDs stimulate apoptosis in vitro. They pointed out that much lower concentrations of NSAIDs are usually detected in the serum of patients given standard doses of NSAIDs. This issue was also raised by Jaime Masferrer who noted that 200 to 300 M indomethacin was required to suppress cell proliferation in vitro, whereas plasma concentrations of this drug are much lower. Despite these concerns, other participants felt that the concentrations of NSAIDs used in at least some of the in vitro experiments were clinically relevant. For example, Daniel Hwang noted that the concentrations of NSAIDs that suppress cytokine -mediated induction of COX -2 in vitro are clinically attainable. He indicated that 1 g of mefenamic acid given four times daily produced steady -state concentrations of 80 M [ 43 ] . Rifat Pamukcu ( Cell Pathways, Inc. ) indicated that the concentrations of sulindac metabolites within the lumen of the gastrointestinal tract are higher than those in plasma. He also reported that both sulindac sulfone and sulindac sulfide are sequestered within the cell; this results, in turn, in intracellular concentrations of both sulindac metabolites that appear to be substantially higher than observed in plasma. Hence, some of the COX -independent mechanisms of action may be clinically relevant for the metabolites of sulindac.
A discussion ensued concerning the potential use of COX knockout mice to determine whether clinically relevant doses of NSAIDs reduce tumorigenesis, in part, by COX -independent mechanisms. Lawrence Marnett suggested that it would be worthwhile to evaluate whether selective COX -2 inhibitors suppressed tumorigenesis in COX -2 knockout mice. If COX -2 -selective inhibitors still show chemopreventive effects, this would represent a COX -2 -independent effect of the agent. Robert Langenbach stated that this was a good idea, but indicated that such studies were not easy to perform because the number of tumors is low in COX -2 knockout mice in the first place.
4. In considering ongoing chemoprevention trials utilizing NSAIDs or selective COX -2 inhibitors, what problems exist concerning patient eligibility criteria? Should more effort be made to correlate an individual's clinical response with known genetic polymorphisms for enzymes involved in the metabolism of NSAIDs?
Maria Elena Martinez ( Arizona Cancer Center, Tucson, AZ ) pointed out that use of aspirin is relatively common among subjects who are potential participants in chemoprevention trials. For example, some individuals may use low -dose aspirin to protect against cardiovascular disease. If one excludes individuals who use aspirin regardless of dose, subject recruitment will be extremely difficult and costly. If use of low -dose aspirin is permitted, it is unclear whether the therapeutic intervention will cause reductions in recurrence, e.g., colorectal polyp formation, beyond those related to the use of aspirin. Although there is no straightforward answer to this dilemma, the group did not feel that there was compelling evidence yet that low -dose aspirin protected against colorectal neoplasia. In clinical trials, stratifying patients according to use of aspirin may prove helpful until further information is available.
Dr. Martinez discussed preliminary findings concerning the use of aspirin and colorectal adenoma recurrence stratified by NAT2 genotype. The protective effect of aspirin appeared to be stronger among slow acetylators than rapid acetylators. This finding suggests that the efficacy of aspirin in reducing the risk of colorectal neoplasia may be modified by genetic polymorphisms of enzymes involved in the metabolism of NSAIDs. Clearly, this is an important issue that requires additional investigation.
Summary
There is abundant evidence that NSAIDs inhibit tumorigenesis. The results of both genetic and pharmacological studies suggest that inhibiting COX reduces the risk of cancer. Although COX -2 is overexpressed in many malignancies, more needs to be understood about the upstream signaling pathways that regulate its expression. Additionally, the mechanisms by which increased amounts of COX -2 predispose to cancer are incompletely understood. PGs can stimulate angiogenesis and invasiveness while inhibiting apoptosis and immune surveillance. The relative significance of these different protumorigenic effects could vary in different types of tumors or stages of carcinogenesis. Additional insights should be gained by defining the downstream pathways that are activated by PGs via their receptors. Further work is also needed to understand how much of the anticancer activity of NSAIDs can be attributed to inhibition of PG synthesis versus increased amounts of unesterified arachidonic acid in cells.
NSAIDs or related metabolites can affect a variety of molecular targets in addition to COX. Hence, the anticancer activity of NSAIDs may also reflect COX -independent effects. Examples of other possible pharmacological targets include cGMP phosphodiesterases, PPARs, and NF -B. It will be important to determine which of these COXindependent mechanisms are operative in humans given clinically relevant doses of NSAIDs. For example, high concentrations of NSAIDs stimulate PPAR in cultured cells but it is unknown whether PPAR activation occurs when standard doses of NSAIDs are administered in vivo. Clearly, additional studies of NSAIDs will be required to more fully understand the relative importance of COX -dependent and -independent mechanisms of action.
Another significant challenge will be to evaluate whether NSAIDs and related compounds are more effective in chemoprevention or cancer therapy when combined with other agents. Preclinical studies combining inhibitors of EGFR kinase or ornithine decarboxylase with NSAIDs illustrate the promise of this approach [ 44, 45 ] . Ultimately, continued research should provide a more complete understanding of the anticancer properties of NSAIDs as well as insights that will permit the safe and effective use of these agents in both preventing and treating cancer.
